AAV Vector Market Size, Share, By Offering (Product Type, Services), Serotype (AV1, AAV2, AAV5, AAV6, and Others), Gene Delivery Method (Ex Vivo, and In Vivo), Target Therapeutic Area (Genetic Disorders, Hematological Disorders, Infectious Disorders, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, and Others), Application Area (Gene Therapy, Cell Therapy, and Vaccines), End-User (Hospitals, Clinics, Research Institutes, Biopharmaceutical Companies, and Others), and Region - Trends, Analysis, and Forecast till 2035

Report Code: PMI579425 | Publish Date: February 2025 | No. of Pages: 171

Aav Vector Market Size

AAV vector market size was valued at USD 2.3 billion in 2025 and is expected to reach USD 7.8 billion by 2035 growing at a CAGR of 14.3 %.

AAV vectors are viruses used in gene therapy to transfer genetic information into cells. It can infect various cells and enable long-term gene expression without strong immune reactions. The market growth is driven by rising demand, advancements in AAV technology, new vector serotypes, gene editing, personalized therapies, and regulatory support. AAV vectors are safe, efficient, and persist in cells.

AAV Vector Market Size Forecast 2025-2035